CytoDyn Inc. has closed $16.5 million in financing to support the development of leronlimab. This funding reflects strong investor confidence in the company's clinical progress.
CytoDyn Inc. announced the closure of a $16.5 million financing, led by Paulson Investment Company as placement agent. The funds will primarily support clinical development programs and other operational needs. This successful financing highlights strong investor commitment to CytoDyn's growth strategy
Who to call at CytoDyn, and when
A new round usually means CytoDyn is about to hire and buy. The teams that reach out first get the meeting.
An alert the day CytoDyn raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at CytoDyn, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CytoDyn. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
CytoDyn
Location
1111 Main Street
Vancouver, Washington, United States
About
CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CytoDyn raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
VancouverBiotechnologyHealthcareHealth CareTherapeutics